ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) announced initiation of the Phase 1/2 clinical trial of AP32788, an investigational tyrosine kinase inhibitor ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

ARIAD Pharma (ARIA) Announces Completion of European Ops Sale to Incyte (INCY)June 2, 2016 7:36 AM ARIAD Announces Initiation of Phase 1/2 Clinical Trial of AP32788, an Investigational Oral Inhibitor of EGFR and HER2, in Patients with Non-Small Cell Lung CancerMay 31, 2016 7:35 AM